
VistaGen Therapeutics VTGN
€ 0.52
1.5%
Quartalsbericht 2025-Q4
hinzugefügt 12.02.2026
VistaGen Therapeutics Langfristiger Schuldenstrom 2011-2026 | VTGN
Langfristiger Schuldenstrom Jährlich VistaGen Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 561 K | 550 K | 486 K | 433 K | 365 K | 313 K | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 561 K | 313 K | 451 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 48.43 | 9.03 % | $ 13.2 B | ||
|
Fortress Biotech
FBIO
|
2.13 M | $ 2.56 | 3.96 % | $ 71.4 M | ||
|
Galapagos NV
GLPG
|
1.73 M | $ 28.78 | 1.36 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
26 M | $ 27.93 | 1.41 % | $ 17.2 B | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.41 | 1.69 % | $ 6.83 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
InflaRx N.V.
IFRX
|
257 K | $ 2.47 | 25.39 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 76.96 | 2.27 % | $ 12.3 B | ||
|
Kamada Ltd.
KMDA
|
2.12 M | $ 8.3 | 1.1 % | $ 260 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 95.07 | -0.45 % | $ 27.2 B | ||
|
Kymera Therapeutics
KYMR
|
11.9 M | $ 86.14 | 4.15 % | $ 7.28 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
1.27 M | $ 229.83 | -1.06 % | $ 4.2 B | ||
|
INmune Bio
INMB
|
623 K | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Liquidia Corporation
LQDA
|
900 K | $ 41.84 | 4.26 % | $ 3.6 B | ||
|
Mirum Pharmaceuticals
MIRM
|
2.14 M | $ 107.42 | 1.52 % | $ 5.39 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.32 | -0.13 % | $ 3.7 B | ||
|
MannKind Corporation
MNKD
|
2.11 M | $ 3.68 | 28.5 % | $ 1.12 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | 0.55 % | $ 651 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.47 | -8.44 % | $ 5.71 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.86 | 1.88 % | $ 3.04 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Puma Biotechnology
PBYI
|
1.31 M | $ 7.5 | 2.04 % | $ 375 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B |